Citizens Jmp Has Lowered Expectations for Compass Therapeutics (NASDAQ:CMPX) Stock Price

Compass Therapeutics (NASDAQ:CMPX) had its target price dropped by Citizens Jmp to $4.00 in a report released on Wednesday, September 23rd, Benzinga reports. The brokerage presently has a “market outperform” rating on the stock. Citizens Jmp’s price objective points to a potential upside of 279.15% from the company’s previous close.

A number of other research analysts also recently commented on CMPX. Piper Sandler increased their price objective on shares of Compass Therapeutics from $4.00 to $6.00 and gave the company an “overweight” rating in a research note on Friday, August 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of Compass Therapeutics in a research report on Friday, July 17th. Stifel Nicolaus set a $6.00 target price on shares of Compass Therapeutics in a research note on Monday, June 1st. Citigroup reaffirmed a “market outperform” rating on shares of Compass Therapeutics in a research report on Wednesday, September 23rd. Finally, Wall Street Zen lowered Compass Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $10.21.

Compass Therapeutics Trading Down 4.1%

NASDAQ CMPX traded down $0.05 during mid-day trading on Wednesday, reaching $1.06. 477,774 shares of the company’s stock traded hands, compared to its average volume of 4,536,928. Compass Therapeutics has a 1-year low of $1.06 and a 1-year high of $6.88. The company has a fifty day simple moving average of $2.05 and a 200-day simple moving average of $2.80. The company has a market cap of $189.99 million, a price-to-earnings ratio of -2.64 and a beta of 0.95.

Compass Therapeutics (NASDAQ:CMPX) last announced its earnings results on Thursday, August 6th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.02). Equities research analysts forecast that Compass Therapeutics will post -0.47 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of CMPX. Parallel Advisors LLC bought a new position in Compass Therapeutics in the first quarter worth about $28,000. HB Wealth Management LLC bought a new position in shares of Compass Therapeutics during the second quarter valued at approximately $29,000. State of Wyoming bought a new position in shares of Compass Therapeutics during the second quarter valued at approximately $31,000. Wealthcare Capital Partners LLC acquired a new stake in shares of Compass Therapeutics during the 2nd quarter worth approximately $43,000. Finally, Walleye Trading LLC acquired a new stake in shares of Compass Therapeutics during the 2nd quarter worth approximately $55,000. 68.43% of the stock is owned by institutional investors and hedge funds.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc is a clinical-stage biotechnology company focused on developing antibody-based medicines designed to activate and direct the immune system against cancer and other serious diseases. The company’s research is centered on immuno-oncology, with the goal of creating therapies that can stimulate antitumor immune responses and improve outcomes for patients.

Compass Therapeutics has developed a pipeline of proprietary antibody therapeutics, including CTX-471, an investigational monoclonal antibody intended to activate CD137, an immune-stimulatory receptor found on certain immune cells.